Intratumoral administration of poly‐ICLC enhances the antitumor effects of anti‐PD ‐1
Article Swipe
Shin‐Yun Liu
,
Chia‐Lang Hsu
,
Shih‐Feng Yang
,
Mei–Hsuan Lee
,
Jin‐Chuan Sheu
,
Meng–Tzu Weng
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1002/jhbp.12088
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1002/jhbp.12088
Background Immune checkpoint inhibitors are effective to treat hepatocellular carcinoma (HCC) yet only successful in a small part of patients. This study aimed to investigate whether poly‐ICLC, an immune stimulant, can enhance the antitumor effects of anti‐PD‐1 on mouse HCC. Methods We established two syngeneic HCC mouse models with BNL cells in BALB/c mice and Hep‐55.1 C cells in C57BL/6 J mice. Mice with subcutaneous HCC tumors received one of five treatments: control, anti‐PD‐1, intratumoral (IT) poly‐ICLC, anti‐PD‐1 plus intramuscular (IM) poly‐ICLC, or anti‐PD‐1 plus IT poly‐ICLC. Tumor volumes were measured, CD8+ T lymphocytes in tumors and spleen were analyzed, and interferon‐γ activity was assessed by ELISpot. Immune cell types and abundance were evaluated with NanoString nCounter IO360 panels. Results Cotreatment with poly‐ICLC significantly enhanced the antitumor effects of anti‐PD‐1, with IT administration being more effective than IM. IT poly‐ICLC also induced more significant CD8 + T cell infiltration and interferon‐γ activity in the tumor and spleen, and more upregulation of both interferon‐γ and M1 macrophage signals in the tumor microenvironment while downregulating several cancer‐promoting pathways. Conclusions Combination therapy with poly‐ICLC, especially through IT route, and anti‐PD‐1 provides significantly greater antitumor effects than anti‐PD‐1 monotherapy in syngeneic mouse models of HCC.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1002/jhbp.12088
- https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jhbp.12088
- OA Status
- bronze
- Cited By
- 2
- References
- 33
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4404365213
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4404365213Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1002/jhbp.12088Digital Object Identifier
- Title
-
Intratumoral administration of poly‐
ICLC enhances the antitumor effects of anti‐PD ‐1Work title - Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-11-13Full publication date if available
- Authors
-
Shin‐Yun Liu, Chia‐Lang Hsu, Shih‐Feng Yang, Mei–Hsuan Lee, Jin‐Chuan Sheu, Meng–Tzu WengList of authors in order
- Landing page
-
https://doi.org/10.1002/jhbp.12088Publisher landing page
- PDF URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jhbp.12088Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jhbp.12088Direct OA link when available
- Concepts
-
Immune system, Cancer research, Spleen, Tumor microenvironment, CD8, Medicine, ELISPOT, Interferon, Hepatocellular carcinoma, Immunology, Pharmacology, ChemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
2Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 2Per-year citation counts (last 5 years)
- References (count)
-
33Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4404365213 |
|---|---|
| doi | https://doi.org/10.1002/jhbp.12088 |
| ids.doi | https://doi.org/10.1002/jhbp.12088 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/39538381 |
| ids.openalex | https://openalex.org/W4404365213 |
| fwci | 1.07549348 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000818 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Animals |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D051379 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Mice |
| mesh[2].qualifier_ui | Q000008 |
| mesh[2].descriptor_ui | D011070 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | administration & dosage |
| mesh[2].descriptor_name | Poly I-C |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D008810 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Mice, Inbred C57BL |
| mesh[4].qualifier_ui | Q000008 |
| mesh[4].descriptor_ui | D000082082 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | administration & dosage |
| mesh[4].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[5].qualifier_ui | Q000188 |
| mesh[5].descriptor_ui | D006528 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | drug therapy |
| mesh[5].descriptor_name | Carcinoma, Hepatocellular |
| mesh[6].qualifier_ui | Q000473 |
| mesh[6].descriptor_ui | D006528 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | pathology |
| mesh[6].descriptor_name | Carcinoma, Hepatocellular |
| mesh[7].qualifier_ui | Q000276 |
| mesh[7].descriptor_ui | D006528 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | immunology |
| mesh[7].descriptor_name | Carcinoma, Hepatocellular |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D008807 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Mice, Inbred BALB C |
| mesh[9].qualifier_ui | Q000188 |
| mesh[9].descriptor_ui | D008113 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | drug therapy |
| mesh[9].descriptor_name | Liver Neoplasms |
| mesh[10].qualifier_ui | Q000473 |
| mesh[10].descriptor_ui | D008113 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | pathology |
| mesh[10].descriptor_name | Liver Neoplasms |
| mesh[11].qualifier_ui | Q000008 |
| mesh[11].descriptor_ui | D011091 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | administration & dosage |
| mesh[11].descriptor_name | Polyesters |
| mesh[12].qualifier_ui | Q000037 |
| mesh[12].descriptor_ui | D061026 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | antagonists & inhibitors |
| mesh[12].descriptor_name | Programmed Cell Death 1 Receptor |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D045744 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Cell Line, Tumor |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D004195 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Disease Models, Animal |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D015552 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Injections, Intralesional |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D018414 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | CD8-Positive T-Lymphocytes |
| mesh[17].qualifier_ui | Q000031 |
| mesh[17].descriptor_ui | D002266 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | analogs & derivatives |
| mesh[17].descriptor_name | Carboxymethylcellulose Sodium |
| mesh[18].qualifier_ui | Q000031 |
| mesh[18].descriptor_ui | D011107 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | analogs & derivatives |
| mesh[18].descriptor_name | Polylysine |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D000818 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Animals |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D051379 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Mice |
| mesh[21].qualifier_ui | Q000188 |
| mesh[21].descriptor_ui | D006528 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | drug therapy |
| mesh[21].descriptor_name | Carcinoma, Hepatocellular |
| mesh[22].qualifier_ui | Q000473 |
| mesh[22].descriptor_ui | D006528 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | pathology |
| mesh[22].descriptor_name | Carcinoma, Hepatocellular |
| mesh[23].qualifier_ui | Q000276 |
| mesh[23].descriptor_ui | D006528 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | immunology |
| mesh[23].descriptor_name | Carcinoma, Hepatocellular |
| mesh[24].qualifier_ui | Q000494 |
| mesh[24].descriptor_ui | D011070 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | pharmacology |
| mesh[24].descriptor_name | Poly I-C |
| mesh[25].qualifier_ui | Q000008 |
| mesh[25].descriptor_ui | D011070 |
| mesh[25].is_major_topic | True |
| mesh[25].qualifier_name | administration & dosage |
| mesh[25].descriptor_name | Poly I-C |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D008807 |
| mesh[26].is_major_topic | True |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Mice, Inbred BALB C |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D008810 |
| mesh[27].is_major_topic | True |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Mice, Inbred C57BL |
| mesh[28].qualifier_ui | Q000188 |
| mesh[28].descriptor_ui | D008113 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | drug therapy |
| mesh[28].descriptor_name | Liver Neoplasms |
| mesh[29].qualifier_ui | Q000473 |
| mesh[29].descriptor_ui | D008113 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | pathology |
| mesh[29].descriptor_name | Liver Neoplasms |
| mesh[30].qualifier_ui | Q000494 |
| mesh[30].descriptor_ui | D000082082 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | pharmacology |
| mesh[30].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D015552 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Injections, Intralesional |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D004195 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Disease Models, Animal |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D045744 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Cell Line, Tumor |
| mesh[34].qualifier_ui | Q000187 |
| mesh[34].descriptor_ui | D018414 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | drug effects |
| mesh[34].descriptor_name | CD8-Positive T-Lymphocytes |
| mesh[35].qualifier_ui | Q000276 |
| mesh[35].descriptor_ui | D018414 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | immunology |
| mesh[35].descriptor_name | CD8-Positive T-Lymphocytes |
| mesh[36].qualifier_ui | Q000037 |
| mesh[36].descriptor_ui | D061026 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | antagonists & inhibitors |
| mesh[36].descriptor_name | Programmed Cell Death 1 Receptor |
| mesh[37].qualifier_ui | Q000031 |
| mesh[37].descriptor_ui | D002266 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | analogs & derivatives |
| mesh[37].descriptor_name | Carboxymethylcellulose Sodium |
| mesh[38].qualifier_ui | Q000031 |
| mesh[38].descriptor_ui | D011107 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | analogs & derivatives |
| mesh[38].descriptor_name | Polylysine |
| type | article |
| title | Intratumoral administration of poly‐ |
| awards[0].id | https://openalex.org/G2780628178 |
| awards[0].funder_id | https://openalex.org/F4320323422 |
| awards[0].display_name | |
| awards[0].funder_award_id | 112‐BIH007 |
| awards[0].funder_display_name | National Taiwan University Hospital |
| biblio.issue | 2 |
| biblio.volume | 32 |
| biblio.last_page | 150 |
| biblio.first_page | 139 |
| topics[0].id | https://openalex.org/T10158 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9997000098228455 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | Cancer Immunotherapy and Biomarkers |
| topics[1].id | https://openalex.org/T11020 |
| topics[1].field.id | https://openalex.org/fields/24 |
| topics[1].field.display_name | Immunology and Microbiology |
| topics[1].score | 0.9997000098228455 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2403 |
| topics[1].subfield.display_name | Immunology |
| topics[1].display_name | Immune Cell Function and Interaction |
| topics[2].id | https://openalex.org/T11313 |
| topics[2].field.id | https://openalex.org/fields/24 |
| topics[2].field.display_name | Immunology and Microbiology |
| topics[2].score | 0.9995999932289124 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2403 |
| topics[2].subfield.display_name | Immunology |
| topics[2].display_name | Immune cells in cancer |
| funders[0].id | https://openalex.org/F4320323422 |
| funders[0].ror | https://ror.org/03nteze27 |
| funders[0].display_name | National Taiwan University Hospital |
| is_xpac | False |
| apc_list.value | 3700 |
| apc_list.currency | USD |
| apc_list.value_usd | 3700 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C8891405 |
| concepts[0].level | 2 |
| concepts[0].score | 0.6665970087051392 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[0].display_name | Immune system |
| concepts[1].id | https://openalex.org/C502942594 |
| concepts[1].level | 1 |
| concepts[1].score | 0.6337398886680603 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[1].display_name | Cancer research |
| concepts[2].id | https://openalex.org/C2780931953 |
| concepts[2].level | 2 |
| concepts[2].score | 0.583949863910675 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q9371 |
| concepts[2].display_name | Spleen |
| concepts[3].id | https://openalex.org/C2776107976 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5279844403266907 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1786433 |
| concepts[3].display_name | Tumor microenvironment |
| concepts[4].id | https://openalex.org/C167672396 |
| concepts[4].level | 3 |
| concepts[4].score | 0.4975467026233673 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q417800 |
| concepts[4].display_name | CD8 |
| concepts[5].id | https://openalex.org/C71924100 |
| concepts[5].level | 0 |
| concepts[5].score | 0.45495760440826416 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[5].display_name | Medicine |
| concepts[6].id | https://openalex.org/C2779053233 |
| concepts[6].level | 4 |
| concepts[6].score | 0.45417237281799316 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q731235 |
| concepts[6].display_name | ELISPOT |
| concepts[7].id | https://openalex.org/C2776178377 |
| concepts[7].level | 2 |
| concepts[7].score | 0.44381651282310486 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q188269 |
| concepts[7].display_name | Interferon |
| concepts[8].id | https://openalex.org/C2778019345 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4123813211917877 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1148337 |
| concepts[8].display_name | Hepatocellular carcinoma |
| concepts[9].id | https://openalex.org/C203014093 |
| concepts[9].level | 1 |
| concepts[9].score | 0.39261722564697266 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[9].display_name | Immunology |
| concepts[10].id | https://openalex.org/C98274493 |
| concepts[10].level | 1 |
| concepts[10].score | 0.3555911183357239 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[10].display_name | Pharmacology |
| concepts[11].id | https://openalex.org/C185592680 |
| concepts[11].level | 0 |
| concepts[11].score | 0.33521440625190735 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[11].display_name | Chemistry |
| keywords[0].id | https://openalex.org/keywords/immune-system |
| keywords[0].score | 0.6665970087051392 |
| keywords[0].display_name | Immune system |
| keywords[1].id | https://openalex.org/keywords/cancer-research |
| keywords[1].score | 0.6337398886680603 |
| keywords[1].display_name | Cancer research |
| keywords[2].id | https://openalex.org/keywords/spleen |
| keywords[2].score | 0.583949863910675 |
| keywords[2].display_name | Spleen |
| keywords[3].id | https://openalex.org/keywords/tumor-microenvironment |
| keywords[3].score | 0.5279844403266907 |
| keywords[3].display_name | Tumor microenvironment |
| keywords[4].id | https://openalex.org/keywords/cd8 |
| keywords[4].score | 0.4975467026233673 |
| keywords[4].display_name | CD8 |
| keywords[5].id | https://openalex.org/keywords/medicine |
| keywords[5].score | 0.45495760440826416 |
| keywords[5].display_name | Medicine |
| keywords[6].id | https://openalex.org/keywords/elispot |
| keywords[6].score | 0.45417237281799316 |
| keywords[6].display_name | ELISPOT |
| keywords[7].id | https://openalex.org/keywords/interferon |
| keywords[7].score | 0.44381651282310486 |
| keywords[7].display_name | Interferon |
| keywords[8].id | https://openalex.org/keywords/hepatocellular-carcinoma |
| keywords[8].score | 0.4123813211917877 |
| keywords[8].display_name | Hepatocellular carcinoma |
| keywords[9].id | https://openalex.org/keywords/immunology |
| keywords[9].score | 0.39261722564697266 |
| keywords[9].display_name | Immunology |
| keywords[10].id | https://openalex.org/keywords/pharmacology |
| keywords[10].score | 0.3555911183357239 |
| keywords[10].display_name | Pharmacology |
| keywords[11].id | https://openalex.org/keywords/chemistry |
| keywords[11].score | 0.33521440625190735 |
| keywords[11].display_name | Chemistry |
| language | en |
| locations[0].id | doi:10.1002/jhbp.12088 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S108612764 |
| locations[0].source.issn | 1868-6974, 1868-6982 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1868-6974 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Journal of Hepato-Biliary-Pancreatic Sciences |
| locations[0].source.host_organization | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_name | Wiley |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_lineage_names | Wiley |
| locations[0].license | |
| locations[0].pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jhbp.12088 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Journal of Hepato-Biliary-Pancreatic Sciences |
| locations[0].landing_page_url | https://doi.org/10.1002/jhbp.12088 |
| locations[1].id | pmid:39538381 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Journal of hepato-biliary-pancreatic sciences |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/39538381 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5004105586 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-3120-6848 |
| authorships[0].author.display_name | Shin‐Yun Liu |
| authorships[0].affiliations[0].raw_affiliation_string | Liver Disease Prevention and Treatment Research Foundation, Taipei, Taiwan |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Shin‐Yun Liu |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Liver Disease Prevention and Treatment Research Foundation, Taipei, Taiwan |
| authorships[1].author.id | https://openalex.org/A5033886049 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-7447-8045 |
| authorships[1].author.display_name | Chia‐Lang Hsu |
| authorships[1].countries | TW |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210131804 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan |
| authorships[1].institutions[0].id | https://openalex.org/I4210131804 |
| authorships[1].institutions[0].ror | https://ror.org/03nteze27 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210131804 |
| authorships[1].institutions[0].country_code | TW |
| authorships[1].institutions[0].display_name | National Taiwan University Hospital |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Chia‐Lang Hsu |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan |
| authorships[2].author.id | https://openalex.org/A5017013207 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-0156-0953 |
| authorships[2].author.display_name | Shih‐Feng Yang |
| authorships[2].affiliations[0].raw_affiliation_string | Liver Disease Prevention and Treatment Research Foundation, Taipei, Taiwan |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Shih‐Feng Yang |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Liver Disease Prevention and Treatment Research Foundation, Taipei, Taiwan |
| authorships[3].author.id | https://openalex.org/A5081595657 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-8017-0434 |
| authorships[3].author.display_name | Mei–Hsuan Lee |
| authorships[3].countries | TW |
| authorships[3].affiliations[0].raw_affiliation_string | Liver Disease Prevention and Treatment Research Foundation, Taipei, Taiwan |
| authorships[3].affiliations[1].institution_ids | https://openalex.org/I4210131804 |
| authorships[3].affiliations[1].raw_affiliation_string | Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan |
| authorships[3].institutions[0].id | https://openalex.org/I4210131804 |
| authorships[3].institutions[0].ror | https://ror.org/03nteze27 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210131804 |
| authorships[3].institutions[0].country_code | TW |
| authorships[3].institutions[0].display_name | National Taiwan University Hospital |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Hsuan‐Shu Lee |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Liver Disease Prevention and Treatment Research Foundation, Taipei, Taiwan |
| authorships[4].author.id | https://openalex.org/A5006106928 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-2503-7139 |
| authorships[4].author.display_name | Jin‐Chuan Sheu |
| authorships[4].countries | TW |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210131804 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan |
| authorships[4].affiliations[1].raw_affiliation_string | Liver Disease Prevention and Treatment Research Foundation, Taipei, Taiwan |
| authorships[4].institutions[0].id | https://openalex.org/I4210131804 |
| authorships[4].institutions[0].ror | https://ror.org/03nteze27 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210131804 |
| authorships[4].institutions[0].country_code | TW |
| authorships[4].institutions[0].display_name | National Taiwan University Hospital |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Jin‐Chuan Sheu |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Liver Disease Prevention and Treatment Research Foundation, Taipei, Taiwan |
| authorships[5].author.id | https://openalex.org/A5007711481 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-4143-6607 |
| authorships[5].author.display_name | Meng–Tzu Weng |
| authorships[5].countries | TW |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210131804 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan |
| authorships[5].affiliations[1].institution_ids | https://openalex.org/I4210131804 |
| authorships[5].affiliations[1].raw_affiliation_string | Department of Medical Research, National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu, Taiwan |
| authorships[5].institutions[0].id | https://openalex.org/I4210131804 |
| authorships[5].institutions[0].ror | https://ror.org/03nteze27 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210131804 |
| authorships[5].institutions[0].country_code | TW |
| authorships[5].institutions[0].display_name | National Taiwan University Hospital |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Meng‐Tzu Weng |
| authorships[5].is_corresponding | True |
| authorships[5].raw_affiliation_strings | Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Department of Medical Research, National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu, Taiwan |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jhbp.12088 |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2024-11-15T00:00:00 |
| display_name | Intratumoral administration of poly‐ |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10158 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9997000098228455 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | Cancer Immunotherapy and Biomarkers |
| related_works | https://openalex.org/W1794808949, https://openalex.org/W2008184737, https://openalex.org/W2414222088, https://openalex.org/W2100609764, https://openalex.org/W2416010474, https://openalex.org/W3037401902, https://openalex.org/W3214021846, https://openalex.org/W1972821856, https://openalex.org/W209514875, https://openalex.org/W2134569739 |
| cited_by_count | 2 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 2 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1002/jhbp.12088 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S108612764 |
| best_oa_location.source.issn | 1868-6974, 1868-6982 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1868-6974 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Journal of Hepato-Biliary-Pancreatic Sciences |
| best_oa_location.source.host_organization | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_name | Wiley |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_lineage_names | Wiley |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jhbp.12088 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Journal of Hepato-Biliary-Pancreatic Sciences |
| best_oa_location.landing_page_url | https://doi.org/10.1002/jhbp.12088 |
| primary_location.id | doi:10.1002/jhbp.12088 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S108612764 |
| primary_location.source.issn | 1868-6974, 1868-6982 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1868-6974 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Journal of Hepato-Biliary-Pancreatic Sciences |
| primary_location.source.host_organization | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_name | Wiley |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_lineage_names | Wiley |
| primary_location.license | |
| primary_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jhbp.12088 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Journal of Hepato-Biliary-Pancreatic Sciences |
| primary_location.landing_page_url | https://doi.org/10.1002/jhbp.12088 |
| publication_date | 2024-11-13 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W4367314878, https://openalex.org/W4323981459, https://openalex.org/W4223422528, https://openalex.org/W2990602950, https://openalex.org/W4200118825, https://openalex.org/W4200158019, https://openalex.org/W3108508734, https://openalex.org/W4220990811, https://openalex.org/W3087683890, https://openalex.org/W3200816639, https://openalex.org/W3087341228, https://openalex.org/W2147557533, https://openalex.org/W2742647944, https://openalex.org/W4313561743, https://openalex.org/W2511266982, https://openalex.org/W2952406594, https://openalex.org/W2010457001, https://openalex.org/W6653110446, https://openalex.org/W2092262181, https://openalex.org/W3102147110, https://openalex.org/W6785918294, https://openalex.org/W2075413744, https://openalex.org/W4205315499, https://openalex.org/W1606264375, https://openalex.org/W2115671319, https://openalex.org/W2619094261, https://openalex.org/W4377104854, https://openalex.org/W2081810806, https://openalex.org/W2101195992, https://openalex.org/W2124144068, https://openalex.org/W2361134965, https://openalex.org/W2936167073, https://openalex.org/W2305924158 |
| referenced_works_count | 33 |
| abstract_inverted_index.+ | 146 |
| abstract_inverted_index.C | 57 |
| abstract_inverted_index.J | 61 |
| abstract_inverted_index.T | 93, 147 |
| abstract_inverted_index.a | 16 |
| abstract_inverted_index.IT | 86, 132, 139, 184 |
| abstract_inverted_index.M1 | 165 |
| abstract_inverted_index.We | 42 |
| abstract_inverted_index.an | 28 |
| abstract_inverted_index.by | 106 |
| abstract_inverted_index.in | 15, 52, 59, 95, 153, 168, 196 |
| abstract_inverted_index.of | 19, 36, 70, 129, 161, 200 |
| abstract_inverted_index.on | 38 |
| abstract_inverted_index.or | 83 |
| abstract_inverted_index.to | 7, 24 |
| abstract_inverted_index.BNL | 50 |
| abstract_inverted_index.CD8 | 145 |
| abstract_inverted_index.HCC | 46, 66 |
| abstract_inverted_index.IM. | 138 |
| abstract_inverted_index.and | 55, 97, 101, 111, 150, 156, 158, 164, 186 |
| abstract_inverted_index.are | 5 |
| abstract_inverted_index.can | 31 |
| abstract_inverted_index.one | 69 |
| abstract_inverted_index.the | 33, 126, 154, 169 |
| abstract_inverted_index.two | 44 |
| abstract_inverted_index.was | 104 |
| abstract_inverted_index.yet | 12 |
| abstract_inverted_index.(IM) | 81 |
| abstract_inverted_index.(IT) | 76 |
| abstract_inverted_index.CD8+ | 92 |
| abstract_inverted_index.HCC. | 40, 201 |
| abstract_inverted_index.Mice | 63 |
| abstract_inverted_index.This | 21 |
| abstract_inverted_index.also | 141 |
| abstract_inverted_index.both | 162 |
| abstract_inverted_index.cell | 109, 148 |
| abstract_inverted_index.five | 71 |
| abstract_inverted_index.mice | 54 |
| abstract_inverted_index.more | 135, 143, 159 |
| abstract_inverted_index.only | 13 |
| abstract_inverted_index.part | 18 |
| abstract_inverted_index.plus | 79, 85 |
| abstract_inverted_index.than | 137, 193 |
| abstract_inverted_index.were | 90, 99, 113 |
| abstract_inverted_index.with | 49, 64, 115, 122, 131, 180 |
| abstract_inverted_index.(HCC) | 11 |
| abstract_inverted_index.IO360 | 118 |
| abstract_inverted_index.Tumor | 88 |
| abstract_inverted_index.aimed | 23 |
| abstract_inverted_index.being | 134 |
| abstract_inverted_index.cells | 51, 58 |
| abstract_inverted_index.mice. | 62 |
| abstract_inverted_index.mouse | 39, 47, 198 |
| abstract_inverted_index.small | 17 |
| abstract_inverted_index.study | 22 |
| abstract_inverted_index.treat | 8 |
| abstract_inverted_index.tumor | 155, 170 |
| abstract_inverted_index.types | 110 |
| abstract_inverted_index.while | 172 |
| abstract_inverted_index.BALB/c | 53 |
| abstract_inverted_index.Immune | 2, 108 |
| abstract_inverted_index.immune | 29 |
| abstract_inverted_index.models | 48, 199 |
| abstract_inverted_index.route, | 185 |
| abstract_inverted_index.spleen | 98 |
| abstract_inverted_index.tumors | 67, 96 |
| abstract_inverted_index.C57BL/6 | 60 |
| abstract_inverted_index.Methods | 41 |
| abstract_inverted_index.Results | 120 |
| abstract_inverted_index.effects | 35, 128, 192 |
| abstract_inverted_index.enhance | 32 |
| abstract_inverted_index.greater | 190 |
| abstract_inverted_index.induced | 142 |
| abstract_inverted_index.panels. | 119 |
| abstract_inverted_index.several | 174 |
| abstract_inverted_index.signals | 167 |
| abstract_inverted_index.spleen, | 157 |
| abstract_inverted_index.therapy | 179 |
| abstract_inverted_index.through | 183 |
| abstract_inverted_index.volumes | 89 |
| abstract_inverted_index.whether | 26 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.ELISpot. | 107 |
| abstract_inverted_index.activity | 103, 152 |
| abstract_inverted_index.assessed | 105 |
| abstract_inverted_index.control, | 73 |
| abstract_inverted_index.enhanced | 125 |
| abstract_inverted_index.nCounter | 117 |
| abstract_inverted_index.provides | 188 |
| abstract_inverted_index.received | 68 |
| abstract_inverted_index.abundance | 112 |
| abstract_inverted_index.analyzed, | 100 |
| abstract_inverted_index.antitumor | 34, 127, 191 |
| abstract_inverted_index.carcinoma | 10 |
| abstract_inverted_index.effective | 6, 136 |
| abstract_inverted_index.evaluated | 114 |
| abstract_inverted_index.measured, | 91 |
| abstract_inverted_index.pathways. | 176 |
| abstract_inverted_index.patients. | 20 |
| abstract_inverted_index.syngeneic | 45, 197 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Hep‐55.1 | 56 |
| abstract_inverted_index.NanoString | 116 |
| abstract_inverted_index.checkpoint | 3 |
| abstract_inverted_index.especially | 182 |
| abstract_inverted_index.inhibitors | 4 |
| abstract_inverted_index.macrophage | 166 |
| abstract_inverted_index.stimulant, | 30 |
| abstract_inverted_index.successful | 14 |
| abstract_inverted_index.Combination | 178 |
| abstract_inverted_index.Conclusions | 177 |
| abstract_inverted_index.Cotreatment | 121 |
| abstract_inverted_index.established | 43 |
| abstract_inverted_index.investigate | 25 |
| abstract_inverted_index.lymphocytes | 94 |
| abstract_inverted_index.monotherapy | 195 |
| abstract_inverted_index.poly‐ICLC | 123, 140 |
| abstract_inverted_index.significant | 144 |
| abstract_inverted_index.treatments: | 72 |
| abstract_inverted_index.infiltration | 149 |
| abstract_inverted_index.intratumoral | 75 |
| abstract_inverted_index.poly‐ICLC, | 27, 77, 82, 181 |
| abstract_inverted_index.poly‐ICLC. | 87 |
| abstract_inverted_index.subcutaneous | 65 |
| abstract_inverted_index.upregulation | 160 |
| abstract_inverted_index.anti‐PD‐1 | 37, 78, 84, 187, 194 |
| abstract_inverted_index.intramuscular | 80 |
| abstract_inverted_index.significantly | 124, 189 |
| abstract_inverted_index.administration | 133 |
| abstract_inverted_index.anti‐PD‐1, | 74, 130 |
| abstract_inverted_index.downregulating | 173 |
| abstract_inverted_index.hepatocellular | 9 |
| abstract_inverted_index.interferon‐γ | 102, 151, 163 |
| abstract_inverted_index.microenvironment | 171 |
| abstract_inverted_index.cancer‐promoting | 175 |
| cited_by_percentile_year.max | 97 |
| cited_by_percentile_year.min | 95 |
| corresponding_author_ids | https://openalex.org/A5007711481 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 6 |
| corresponding_institution_ids | https://openalex.org/I4210131804 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.75 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.77828665 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |